By administration of 13C glucose, it is possible to enrich 13C, a

By administration of 13C glucose, it is possible to enrich 13C, allowing for more advanced determinations, such as examining glycogen synthesis rate and quantifying organelle and mitochondrial activity during the TCA cycle. Positron emission tomography Positron emission tomography (PET) is an imaging technique which is employed to image the biodistribution of a compound of interest labeled with a positron-emitting atom, for example an 18F or 11C. The most commonly employed PET imaging agent is 18F-fluorodeoxyglucose (FDG), a glucose analog which is widely employed to study glucose metabolism across multiple tissue types. 18F-FDG penetrates

the cell membrane and is phosphorylated to FDG-6-phosphate and is no longer metabolized and thus is trapped within the cell. It builds up in the cell in proportion to the rate of glucose transport across the cell membrane and also small molecule library screening in relation to the activities of hexokinase and glucose-6-phospotase within the cell. In skeletal muscle, FDG imaging has been employed to study glucose utilization. When used in conjunction with compartmental modeling, this approach has been employed to dissect the rate of glucose utilization in terms of the components of cell membrane transport and phosphorylative activity in insulin resistance associated with both obesity and diabetes [144, 145]. Another application of PET which is BGB324 relevant to skeletal muscle is the use

of 11C-methyl-methionine

selleck inhibitor to estimate the rate of protein synthesis. This agent accumulates in skeletal muscle as 11C-labeled protein, and the use of this methylated agent has advantages over radiolabeled leucine in that the latter accumulates in the blood as 11C-labeled CO2. Fischmann and others have validated this technique against skeletal muscle biopsy and have used it to outline the rate of skeletal muscle protein synthesis in healthy young volunteers [146–148]. Conclusions Sarcopenia represents a set of outcomes, including the primary outcomes of loss of skeletal muscle strength and endurance, and secondary outcomes which include loss of mobility and increased risk of disability and oxyclozanide mortality. The bulk changes of muscle tissue which lead to these outcomes result from multiple processes occurring at the cellular level. These processes impact the performance of muscle by reducing the number of fibers and the performance of individual fibers. Age-related loss of motor neurons results in denervation of entire fibers, with a concomitant adaptive process that recruits some but not all of these of these fibers into surviving motor units. Changes in the hormonal and inflammatory milieu result in impairment of protein synthesis and increased protein degradation. Buildup or ROS may result in mitochondrial dysfunction which impairs muscle respiration and may result in fiber deterioration through loss of myonuclei.

Comments are closed.